Trial Profile

Randomized, Multi-center Phase II Study to Evaluate the Efficacy and Safety of AHB-137 in HBeAg-negative CHB Subjects Under Stable Nucleos(t)Ide Analogue (NA) Treatment

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 14 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs AHB 137 (Primary)
Indications Hepatitis B
Focus Therapeutic Use
Sponsors AusperBio

Most Recent Events

07 May 2025 Interim results presented in an AusperBio Therapeutics media release.
07 May 2025 According to an AusperBio Therapeutics media release, data from this trial will be presented at the annual European Association for the Study of the Liver (EASL) Congress 2025, held May 7-10 in Amsterdam, the Netherlands.
23 Apr 2025 Planned primary completion date changed from 1 Apr 2025 to 2 Jun 2025.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com